NanoViricides Inc. (NNVC)

[Its_lose_not_loose]

Afternoon chuckle. Written as if viricides actually work.

The lawsuits should go after not NNVC itself but the personal assets of Diwan and any offending BOD members who perpetuated the magnamnimous dole out of monies and bonuses and stock to Diwan for years without holding him accountable for anything for anything above D&O insurance so as not to destroy the company. Yes, I agree with a settling or even avoidance of a series of lawsuits by an imminent total overhauling of the company structure is the best solution. This is the way it could and possibly should be accomplished.

1. Resignation or removal of Anil Diwan as President and Chairman and Meeta Vyas ass CFO of NNVC. (they are still the primary owners of NNVC stock through Theracour and personal stock ownership and thus be major beneficiaries of the company's success down the road). A new CFO to be hired at much less than Anil's NNVC salary level, and FDA GMP knowledgable quality assurance person hired. Both the CFO and such a QA person can be hired for less than Anil's total current annual compensation.

2. Bring in a brand new Director as Corporate Chairman.of the Board of Directors.

3.. Anil should license in VZV to NNVC from Theracour for just a token buck to create goodwill and restore his reputation and credibility, but with a very handsome and generous double digit royalty to Theracour on future sales put in place in the agreement by NNVC, so Theracour is motivated to make the IND programs actually succeed and meet set time deadlines. The brand new NNVC-Theracour agreement that replaces all previous ones should set milestones and timelines that Theracour is obligated to meet.

4. Theracour/AllExcel employees working on NNVC projects become employees of NNVC for the period until at least the first Herpecide drug approval (their salaries and benefits currently get paid through NNVC anyway, with Anil profiting from a 30% add-on on everyone's salary!). They gear up for FDA compliant clinical batch manufacture as soon as the GLP tox batch material is (finally!) delivered.

5. AllExcel employees who work on projects outside NNVC's scope should vacate NNVC's Shelton and West Haven facilities and carry out their work elsewhere, because the FDA would not like operational persons from the non-sponsor company milling around. All GMP manufacture for clinical trial materials to be carried out under Dr. T's control rather than Anil's. The West Haven facility that is hardly ever if ever used should be vacated and closed so there are operational cost savings to NNVC. Additional quality control staff can be hired from the cost savings of the annual rent being paid by NNVC currently on that unused old facility.

6. Access to capital markets by the CEO to less than toxic debt financing means, to bring in credible institutional biotech investors, which is not currently not very feasible with Diwan's checkered reputation on the Street. Capital raises in succession for Phase 1 and Phase 2.

7. Completion of GLP toxicology package studies on the topical skin product. File an IND. Commence the Phase 1 study.

8. Develop new formulations for genital herpes and ocular keratitis in the laboratory,as the next clinical candidates in the company pipeline once the first Phase 1 safety trial begins.